Physician profile
Brad Moody
NPI 1073793899
$11,265.58
in general payments reported to CMS, 2019-2025
48 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,748 · 2020: $283 · 2021: $104 · 2022: $543 · 2023: $471 · 2024: $489 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.16 |
| Education | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,718.42 | 2019 | |
| Organogenesis INC. | $399.82 | 2019-2024 | Puraply, Affinity |
| Melinta Therapeutics, LLC | $320.72 | 2019-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Harmony Biosciences LLC | $281.64 | 2024-2025 | |
| Integra Lifesciences Corporation | $251.01 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Paratek Pharmaceuticals, INC. | $223.59 | 2019-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $195.63 | 2019-2025 | Imfinzi |
| Smith+Nephew, INC. | $188.41 | 2019-2025 | Renasys Go V2 Home |
| Kerecis Limited | $141.50 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Cumberland Pharmaceuticals, INC. | $126.12 | 2019-2022 | |
| Urgo Medical North America, LLC | $116.13 | 2025 | Urgoclean Ag, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| E.R. Squibb & Sons, L.L.C. | $108.80 | 2020-2023 | |
| Abbvie INC. | $89.68 | 2022-2023 | |
| Next Science LLC | $87.58 | 2022 | |
| Kci USA, INC. | $86.07 | 2019-2023 | Prevena, V.A.C. Veraflo |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $77.81 | 2019-2024 | |
| Allergan, INC. | $62.46 | 2019-2020 | |
| Braintree Laboratories, INC. | $55.22 | 2023-2024 | Sutab, Suflave |
| Davol INC. | $53.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $45.74 | 2019 | |
| Ethicon US, LLC | $45.19 | 2019-2025 | Echelon Flex, Echelon; Endopath |
| Intra-Sana Laboratories | $42.57 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Solventum Corporation | $40.50 | 2024-2025 | Activ.A.C., Promogran Prisma, V.A.C. Veraflo |
| Covidien LP | $35.12 | 2019-2020 | |
| Karl Storz Endoscopy-America | $35.11 | 2025 | |
| Bsn Medical INC | $33.21 | 2025 | |
| Osiris Therapeutics INC. | $30.96 | 2019 | |
| Myriad Genetic Laboratories, INC. | $29.34 | 2021 | |
| Medtronic, INC. | $25.07 | 2024 | Signia |
| Misonix INC | $24.44 | 2020 | |
| 3m Company | $22.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.39 | 2025 | |
| Baxter Healthcare | $20.20 | 2022 | |
| Incyte Corporation | $20.15 | 2025 | Jakafi |
| Acera Surgical, INC. | $20.10 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.54 | 2022 | |
| Avanos Medical | $18.14 | 2024 | On-Q* Pump and Accessories |
| Tela Bio, INC. | $16.90 | 2022 | |
| Lilly USA, LLC | $16.49 | 2025 | Zepbound, Mounjaro |
| Bioventus LLC | $15.32 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $13.94 | 2022 | |
| Exact Sciences Corporation | $13.92 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.92 | 2025 | Trintellix |
| Hartmann USA, INC. | $13.69 | 2022 | |
| Celltrion USA INC. | $13.10 | 2023 | Yuflyma |
| Aroa Biosurgery Incorporated | $13.03 | 2019 | |
| Tactile Systems Technology INC | $12.81 | 2023 | Entre Plus, Flexitouch Plus |
| Z-Medica, LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.